Quick Answer
Pulmonx Corp reported Research And Development Expense of $19.49 million for the year ending 2025.
- Pulmonx Corp showed an increase of +10.9% in Research And Development Expense from 2024 to 2025.
- This data is from Pulmonx Corp's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $1.40 million | Q1 2020: $1.57 million | Q2 2020: $1.43 million | Q3 2020: $2.00 million | Q1 2021: $3.03 million | Q2 2021: $3.51 million | Q3 2021: $2.82 million | Q1 2022: $3.53 million | Q2 2022: $3.59 million | Q3 2022: $4.37 million | Q1 2023: $4.25 million | Q2 2023: $5.71 million | Q3 2023: $4.22 million | Q1 2024: $4.21 million | Q2 2024: $5.62 million | Q3 2024: $3.74 million | Q1 2025: $4.76 million | Q2 2025: $5.31 million | Q3 2025: $4.85 million.
- Over the full 8 years of available data (2018 to 2025), Pulmonx Corp's Research And Development Expense has grown by 178.8%.
- Historical annual values: Fiscal year 2025: $19.49 million | Fiscal year 2024: $17.57 million | Fiscal year 2023: $18.08 million | Fiscal year 2022: $15.40 million | Fiscal year 2021: $13.06 million | Fiscal year 2020: $7.46 million | Fiscal year 2019: $6.05 million | Fiscal year 2018: $6.99 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: